The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 17, 2022

Filed:

May. 24, 2018
Applicants:

Technical University of Denmark, KGS. Lyngby, DK;

Nanovi Radiotherapy Aps, KGS. Lyngby, DK;

Inventors:

Thomas Andresen, Vanløse, DK;

Rasmus Irming Jølck, Kgs. Lyngby, DK;

Linda Maria Bruun, Kopenhagens, DK;

Assignees:

TECHNICAL UNIVERSITY OF DENMARK, Kgs. Lyngby, DK;

NANOVI RADIOTHERAPY APS, Kgs. Lyngby, DK;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 49/10 (2006.01); A61K 49/08 (2006.01); A61K 9/00 (2006.01); A61K 47/26 (2006.01); A61K 49/12 (2006.01);
U.S. Cl.
CPC ...
A61K 49/108 (2013.01); A61K 9/0019 (2013.01); A61K 47/26 (2013.01); A61K 49/085 (2013.01); A61K 49/126 (2013.01);
Abstract

Radiation therapy or radiotherapy (RT) is a powerful treatment where precision and accuracy is crucial. Image Guided Radiotherapy (IGRT) facilitates more accurate position verification, correcting for anatomic changes related to internal organ movement. IGRT thereby helps reduce toxicity of radiotherapy and increases relapse-free survival. An inter-correlation point with a fixed position and volume (a marker) can be applied to indicate the point of treatment clearly in both imaging modalities and to localize and track tumors in real time. In this study, we present the development of a marker based on lactose octaacetate:octapropionate 1:1 containing 3 mM PLA-DTPA(Gd), 40% triglyceride, 5% propylene carbonate and 10% XSAIB (sucrose based CT-contrast agent). The injectable marker had high CT contrast (>1000 HU) and displayed clearly visible, stable Tcontrast enhancement (T˜900 ms) in the rim over at least 3 weeks with clinically observable resolution.


Find Patent Forward Citations

Loading…